Agilon Health Adjusts To Recovery Phase, Analyst Is Cautious On Near-Term Fundamentals

JP Morgan analyst updates estimates for Agilon Health, Inc. based on Q4 results and management’s outlook for recovery and growth in 2025-2027.

Latest Ratings for AGL

Date Firm Action From To
Dec 2021 Deutsche Bank Maintains Buy
Nov 2021 SVB Leerink Maintains Outperform
Oct 2021 Jefferies Initiates Coverage On Buy

View More Analyst Ratings for AGL

View the Latest Analyst Ratings

read more

Leave a Reply

Your email address will not be published. Required fields are marked *